Quarterly ResultMay 14, 2026, 09:08 AM
Pulse Biosciences Q1 Net Loss $(18.6)M; Cash $68.3M
AI Summary
Pulse Biosciences reported a net loss of $(18.6) million for Q1 2026, an increase from $(16.8) million in Q1 2025. Product revenue was $0.4 million, up from zero in the prior year. The company ended the quarter with $68.3 million in cash and cash equivalents and announced a strategic realignment to focus on atrial fibrillation treatment, incurring $0.6 million in severance costs.
Key Highlights
- Net loss for Q1 2026 was $(18.6) million, compared to $(16.8) million in Q1 2025.
- Product revenue for Q1 2026 was $0.4 million, up from $0 in Q1 2025.
- Cash and cash equivalents decreased to $68.3 million as of March 31, 2026, from $80.7 million at Dec 31, 2025.
- Net loss per share was $(0.27) for Q1 2026, compared to $(0.25) for Q1 2025.
- Research and development expenses increased to $12.6 million in Q1 2026 from $10.3 million in Q1 2025.
- Selling, general and administrative expenses decreased to $6.6 million in Q1 2026 from $7.7 million in Q1 2025.
- Recognized $0.6 million in severance and one-time termination expenses due to the 2026 Realignment.
- Accumulated deficit reached $481.9 million as of March 31, 2026.
Price Impact
More from PLSE